JP2016516073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516073A5 JP2016516073A5 JP2016503371A JP2016503371A JP2016516073A5 JP 2016516073 A5 JP2016516073 A5 JP 2016516073A5 JP 2016503371 A JP2016503371 A JP 2016503371A JP 2016503371 A JP2016503371 A JP 2016503371A JP 2016516073 A5 JP2016516073 A5 JP 2016516073A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- esterase inhibitor
- hae
- administration
- esterase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 42
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims description 21
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000036765 blood level Effects 0.000 claims 2
- 229940122601 Esterase inhibitor Drugs 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000002329 esterase inhibitor Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 2
- 229940088950 c1 esterase inhibitor (human) Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 102000016917 Complement C1 Human genes 0.000 description 1
- 108010028774 Complement C1 Proteins 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791399P | 2013-03-15 | 2013-03-15 | |
| US61/791,399 | 2013-03-15 | ||
| PCT/US2014/030309 WO2014145519A2 (en) | 2013-03-15 | 2014-03-17 | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017051361A Division JP6422520B2 (ja) | 2013-03-15 | 2017-03-16 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516073A JP2016516073A (ja) | 2016-06-02 |
| JP2016516073A5 true JP2016516073A5 (cg-RX-API-DMAC7.html) | 2017-04-20 |
| JP6184581B2 JP6184581B2 (ja) | 2017-08-23 |
Family
ID=51538486
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503371A Active JP6184581B2 (ja) | 2013-03-15 | 2014-03-17 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2017051361A Active JP6422520B2 (ja) | 2013-03-15 | 2017-03-16 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2018073690A Active JP6473535B2 (ja) | 2013-03-15 | 2018-04-06 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2018073689A Active JP6473534B2 (ja) | 2013-03-15 | 2018-04-06 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2018073691A Active JP6473536B2 (ja) | 2013-03-15 | 2018-04-06 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2019011079A Active JP6877470B2 (ja) | 2013-03-15 | 2019-01-25 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2019011084A Active JP6877472B2 (ja) | 2013-03-15 | 2019-01-25 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2019011082A Active JP6877471B2 (ja) | 2013-03-15 | 2019-01-25 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2021032716A Pending JP2021088599A (ja) | 2013-03-15 | 2021-03-02 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017051361A Active JP6422520B2 (ja) | 2013-03-15 | 2017-03-16 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2018073690A Active JP6473535B2 (ja) | 2013-03-15 | 2018-04-06 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2018073689A Active JP6473534B2 (ja) | 2013-03-15 | 2018-04-06 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2018073691A Active JP6473536B2 (ja) | 2013-03-15 | 2018-04-06 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2019011079A Active JP6877470B2 (ja) | 2013-03-15 | 2019-01-25 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2019011084A Active JP6877472B2 (ja) | 2013-03-15 | 2019-01-25 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2019011082A Active JP6877471B2 (ja) | 2013-03-15 | 2019-01-25 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
| JP2021032716A Pending JP2021088599A (ja) | 2013-03-15 | 2021-03-02 | Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法 |
Country Status (30)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3290046T (lt) | 2013-03-15 | 2019-03-12 | Shire Viropharma Incorporated | C1-inh kompozicijos ir sutrikimų, susijusių su c1 esterazės inhibitoriaus nepakankamumu, prevencijos bei gydymo būdai |
| HRP20190184T1 (hr) | 2013-11-22 | 2019-03-22 | Shire Viropharma Incorporated | Postupci liječenja odbacivanja uzrokovanog protutijelima kod pacijenata s presađenim organom inhibitorom esteraze c1 |
| SG11201706019XA (en) * | 2015-02-20 | 2017-09-28 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
| HK1250623A1 (zh) * | 2015-05-28 | 2019-01-11 | Cornell University | 腺相关病毒介导的c1ei递送作为用於血管性水肿的疗法 |
| CN108463243B (zh) * | 2015-11-19 | 2022-06-14 | 夏尔人类遗传性治疗公司 | 重组人c1酯酶抑制剂及其用途 |
| AU2017305856B2 (en) * | 2016-08-05 | 2024-09-12 | Csl Behring Gmbh | Pharmaceutical formulations of C1 esterase inhibitor |
| JP2019534240A (ja) * | 2016-08-23 | 2019-11-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法 |
| AU2018269656B2 (en) * | 2017-05-16 | 2024-07-11 | Octapharma Ag | C1-esterase inhibitor preparation |
| MX2020008969A (es) | 2018-02-28 | 2021-02-16 | Pharming Intellectual Property B V | Tratamiento y prevencion de preeclampsia. |
| WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| KR20250096878A (ko) | 2018-06-22 | 2025-06-27 | 가부시키가이샤 준텐 바이오 | 복합 상태를 갖는 세포 혼합물을 이용한, 면역 관용을 유도하는 항체 및 유도된 림프구, 또는 유도된 림프구를 이용하는 세포 치료제 및 치료법 |
| US12139537B2 (en) | 2018-06-22 | 2024-11-12 | Junten Bio Co., Ltd. | Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte |
| AU2019288684A1 (en) | 2018-06-22 | 2021-01-21 | Junten Bio Co., Ltd. | Composition for eliciting infectious immunological tolerance |
| EP4079325A1 (en) * | 2019-12-16 | 2022-10-26 | Nipro Corporation | Aggregation inhibitory agent and medical composition and medical device including same |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| US20240342258A1 (en) | 2021-07-09 | 2024-10-17 | Pharming Intellectual Property B.V. | Using c1 esterase inhibitor to treat viral infection-related symptoms |
| KR20230046146A (ko) | 2021-09-29 | 2023-04-05 | 주식회사 엘지에너지솔루션 | 배터리 제어 시스템 및 방법 |
| WO2025090843A1 (en) * | 2023-10-27 | 2025-05-01 | Kansas State University Research Foundation | Small-molecule inhibitors of c1s protease and classical complement pathway |
| CN119823254B (zh) * | 2025-03-14 | 2025-06-03 | 深圳市卫光生物制品股份有限公司 | 一种c1酯酶抑制剂重组变体及其制备方法和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304482A (en) | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
| WO1992022320A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
| DE69429816T2 (de) | 1993-09-01 | 2002-09-19 | Stichting Sanquin Bloedvoorziening, Amsterdam | C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt |
| WO1997022347A1 (en) | 1995-12-18 | 1997-06-26 | Stichting Sanquin Bloedvoorziening | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. |
| AT409336B (de) | 1999-12-22 | 2002-07-25 | Baxter Ag | Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung |
| US7067713B2 (en) * | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| EP1252184B1 (en) | 2000-01-31 | 2008-01-02 | Pharming Intellectual Property B.V. | Human c1 inhibitor produced in the milk of transgenic mammals |
| ATE442862T2 (de) | 2000-10-12 | 2009-10-15 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| DE10112617A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
| WO2004034971A2 (en) | 2002-09-25 | 2004-04-29 | The Center For Blood Research, Inc. | Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
| USRE43691E1 (en) | 2003-05-16 | 2012-09-25 | Pharming Intellectual Property B.V. | C1 inhibitor with short half-life transient treatment |
| US20060233776A1 (en) | 2003-08-19 | 2006-10-19 | Norbert Heimburger | C1-inh as a drug for treating viruses pathogenic to humans |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| EP2529746A1 (en) | 2005-06-06 | 2012-12-05 | Girish J. Kotwal | Methods for treatment or prophylaxis of reperfusion injury |
| EP2433642B1 (en) | 2005-10-21 | 2016-12-07 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| ES2654816T3 (es) * | 2005-12-21 | 2018-02-15 | Pharming Intellectual Property B.V. | Uso del inhibidor C1 para la prevención de lesión de reperfusión de isquemia |
| KR101508668B1 (ko) | 2005-12-21 | 2015-04-06 | 파밍 인텔렉츄얼 프라퍼티 비.브이. | 허혈-재관류 손상의 예방을 위한 ｃ１ 억제제의 용도 |
| US7837992B2 (en) | 2006-06-22 | 2010-11-23 | Beth Israel Deaconess Medical Center | C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis |
| CA2678001C (en) | 2007-02-12 | 2017-07-11 | Stefan Schulte | Therapeutic application of kazal-type serine protease inhibitors |
| CN101969971A (zh) | 2007-11-30 | 2011-02-09 | 雅培制药有限公司 | 蛋白制剂及其制备方法 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US20100143325A1 (en) | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| SI2488203T1 (sl) | 2009-10-16 | 2017-07-31 | Omeros Corporation | Metode za zdravljenje diseminirane intravaskularne koagulacije z inhibiranjem aktivacije masp-2 odvisnega komplementa |
| EP3815708A1 (en) | 2010-03-05 | 2021-05-05 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
| US20130085111A1 (en) * | 2010-03-18 | 2013-04-04 | Thrombolytic Science, Llc | Production of human c1 inhibitor in human cells |
| WO2013013017A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
| JP6190368B2 (ja) | 2011-09-24 | 2017-08-30 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法 |
| DK2793935T3 (en) | 2011-12-22 | 2016-09-05 | Csl Behring Gmbh | Use of C1 inhibitor in the treatment of secondary edema in the central nervous system. |
| WO2013138730A1 (en) | 2012-03-16 | 2013-09-19 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of c1-inhibitors |
| US20160033511A1 (en) | 2013-03-13 | 2016-02-04 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| LT3290046T (lt) * | 2013-03-15 | 2019-03-12 | Shire Viropharma Incorporated | C1-inh kompozicijos ir sutrikimų, susijusių su c1 esterazės inhibitoriaus nepakankamumu, prevencijos bei gydymo būdai |
| JP6889626B2 (ja) * | 2017-06-29 | 2021-06-18 | トキコシステムソリューションズ株式会社 | 燃料供給システム |
| JP6935245B2 (ja) * | 2017-06-29 | 2021-09-15 | 大和ハウス工業株式会社 | 収容ラック |
-
2014
- 2014-03-17 LT LTEP17177676.8T patent/LT3290046T/lt unknown
- 2014-03-17 HU HUE17177676A patent/HUE041837T2/hu unknown
- 2014-03-17 ME MEP-2017-182A patent/ME02865B/me unknown
- 2014-03-17 RS RS20190198A patent/RS58351B1/sr unknown
- 2014-03-17 KR KR1020227016244A patent/KR102579789B1/ko active Active
- 2014-03-17 TR TR2019/00319T patent/TR201900319T4/tr unknown
- 2014-03-17 PL PL14762343T patent/PL2968434T3/pl unknown
- 2014-03-17 ME MEP-2019-45A patent/ME03326B/me unknown
- 2014-03-17 DE DE202014011208.8U patent/DE202014011208U1/de not_active Expired - Lifetime
- 2014-03-17 CN CN201480014712.7A patent/CN105517559A/zh active Pending
- 2014-03-17 JP JP2016503371A patent/JP6184581B2/ja active Active
- 2014-03-17 SG SG11201507616VA patent/SG11201507616VA/en unknown
- 2014-03-17 SM SM20170415T patent/SMT201700415T1/it unknown
- 2014-03-17 MX MX2015011281A patent/MX373965B/es active IP Right Grant
- 2014-03-17 EA EA201591278A patent/EA201591278A1/ru unknown
- 2014-03-17 PT PT147623433T patent/PT2968434T/pt unknown
- 2014-03-17 SI SI201430368T patent/SI2968434T1/sl unknown
- 2014-03-17 KR KR1020217004777A patent/KR20210021146A/ko not_active Ceased
- 2014-03-17 MX MX2020004724A patent/MX389449B/es unknown
- 2014-03-17 PL PL17177676T patent/PL3290046T3/pl unknown
- 2014-03-17 DK DK17177676.8T patent/DK3290046T3/en active
- 2014-03-17 WO PCT/US2014/030309 patent/WO2014145519A2/en not_active Ceased
- 2014-03-17 ES ES14762343.3T patent/ES2639833T3/es active Active
- 2014-03-17 HU HUE14762343A patent/HUE036224T2/hu unknown
- 2014-03-17 RS RS20170802A patent/RS56285B1/sr unknown
- 2014-03-17 SG SG10201707598QA patent/SG10201707598QA/en unknown
- 2014-03-17 KR KR1020157022897A patent/KR20150135242A/ko not_active Ceased
- 2014-03-17 PT PT17177676T patent/PT3290046T/pt unknown
- 2014-03-17 KR KR1020217033628A patent/KR102430453B1/ko active Active
- 2014-03-17 BR BR112015023207A patent/BR112015023207A8/pt not_active Application Discontinuation
- 2014-03-17 CN CN202010362851.6A patent/CN111529708A/zh active Pending
- 2014-03-17 EP EP18206413.9A patent/EP3508213A1/en not_active Withdrawn
- 2014-03-17 LT LTEP14762343.3T patent/LT2968434T/lt unknown
- 2014-03-17 SM SM20190141T patent/SMT201900141T1/it unknown
- 2014-03-17 HR HRP20171269TT patent/HRP20171269T1/hr unknown
- 2014-03-17 CA CA3054718A patent/CA3054718A1/en not_active Abandoned
- 2014-03-17 GB GB1519921.9A patent/GB2530921B/en active Active
- 2014-03-17 SI SI201431032T patent/SI3290046T1/sl unknown
- 2014-03-17 DK DK14762343.3T patent/DK2968434T3/en active
- 2014-03-17 AU AU2014232912A patent/AU2014232912A1/en not_active Abandoned
- 2014-03-17 ES ES17177676T patent/ES2713004T3/es active Active
- 2014-03-17 EP EP17177676.8A patent/EP3290046B1/en active Active
- 2014-03-17 EP EP14762343.3A patent/EP2968434B1/en not_active Revoked
- 2014-03-17 CA CA2904543A patent/CA2904543C/en active Active
-
2015
- 2015-08-28 MX MX2021011946A patent/MX2021011946A/es unknown
- 2015-09-10 IL IL241549A patent/IL241549B/en active IP Right Grant
- 2015-09-15 US US14/855,168 patent/US9616111B2/en active Active
- 2015-10-13 ZA ZA2015/07604A patent/ZA201507604B/en unknown
-
2017
- 2017-01-20 US US15/411,744 patent/US20170224788A1/en not_active Abandoned
- 2017-03-16 JP JP2017051361A patent/JP6422520B2/ja active Active
- 2017-09-12 CY CY20171100961T patent/CY1119419T1/el unknown
- 2017-10-12 ZA ZA2017/06929A patent/ZA201706929B/en unknown
- 2017-12-11 US US15/837,938 patent/US10130690B2/en active Active
- 2017-12-11 US US15/837,677 patent/US10080788B2/en active Active
- 2017-12-11 US US15/837,693 patent/US10105423B2/en active Active
- 2017-12-11 US US15/837,969 patent/US10201595B2/en active Active
-
2018
- 2018-04-06 JP JP2018073690A patent/JP6473535B2/ja active Active
- 2018-04-06 JP JP2018073689A patent/JP6473534B2/ja active Active
- 2018-04-06 JP JP2018073691A patent/JP6473536B2/ja active Active
- 2018-08-02 US US16/053,457 patent/US11534482B2/en active Active
- 2018-08-10 HK HK18110262.0A patent/HK1250912B/en unknown
- 2018-09-05 US US16/122,015 patent/US20190160158A1/en not_active Abandoned
- 2018-09-17 AU AU2018229558A patent/AU2018229558B2/en active Active
- 2018-10-12 ZA ZA2018/06793A patent/ZA201806793B/en unknown
-
2019
- 2019-01-25 JP JP2019011079A patent/JP6877470B2/ja active Active
- 2019-01-25 JP JP2019011084A patent/JP6877472B2/ja active Active
- 2019-01-25 JP JP2019011082A patent/JP6877471B2/ja active Active
- 2019-02-11 HR HRP20190270TT patent/HRP20190270T1/hr unknown
- 2019-03-15 CY CY20191100308T patent/CY1121653T1/el unknown
- 2019-10-02 US US16/591,184 patent/US11364288B2/en active Active
-
2020
- 2020-05-15 AU AU2020203183A patent/AU2020203183B2/en active Active
- 2020-07-19 IL IL276153A patent/IL276153B/en unknown
-
2021
- 2021-03-02 JP JP2021032716A patent/JP2021088599A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516073A5 (cg-RX-API-DMAC7.html) | ||
| JP2016514132A5 (cg-RX-API-DMAC7.html) | ||
| WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
| WO2021050953A8 (en) | Compositions and methods for the delivery of therapeutic biologics for treatment of disease | |
| JP2018502836A5 (cg-RX-API-DMAC7.html) | ||
| JP2015187125A5 (cg-RX-API-DMAC7.html) | ||
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| JP2018509388A5 (cg-RX-API-DMAC7.html) | ||
| JP2019535651A5 (cg-RX-API-DMAC7.html) | ||
| JP2016517401A5 (cg-RX-API-DMAC7.html) | ||
| JP2016517421A5 (cg-RX-API-DMAC7.html) | ||
| JP2017503014A5 (cg-RX-API-DMAC7.html) | ||
| JP2021509916A5 (cg-RX-API-DMAC7.html) | ||
| JP2015502389A5 (cg-RX-API-DMAC7.html) | ||
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| JP2019501881A5 (cg-RX-API-DMAC7.html) | ||
| US11000577B2 (en) | Compositions and methods for treating neonatal biliary atresia | |
| JP2019501925A5 (cg-RX-API-DMAC7.html) | ||
| JP2014530246A5 (cg-RX-API-DMAC7.html) | ||
| JP2018530525A5 (cg-RX-API-DMAC7.html) | ||
| RU2018132694A (ru) | Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста | |
| Zorenko et al. | Pharmacokinetic properties, safety and tolerability of new b-domain deleted recombinant factor VIII (Octofactor) in patients with severe and moderately severe hemophilia A | |
| WO2009070564A3 (en) | Compositions and methods for prevention of infection in transcutaneous osseointegrated implants | |
| JP2018509395A5 (cg-RX-API-DMAC7.html) | ||
| JP2015500836A5 (cg-RX-API-DMAC7.html) |